作者
Derek A Franklin, Joe T Sharick, Paula I Ericsson-Gonzalez, Violeta Sanchez, Phillip T Dean, Susan R Opalenik, Stefano Cairo, Jean-Gabriel Judde, Michael T Lewis, Jenny C Chang, Melinda E Sanders, Rebecca S Cook, Melissa C Skala, Jennifer Bordeaux, Jehovana Orozco Bender, Christine Vaupel, Gary Geiss, Douglas Hinerfeld, Justin M Balko
发表日期
2020/8/6
期刊
JCI insight
卷号
5
期号
15
出版商
American Society for Clinical Investigation
简介
Triple-negative breast cancers (TNBCs) are heterogeneous and aggressive, with high mortality rates. TNBCs frequently respond to chemotherapy, yet many patients develop chemoresistance. The molecular basis and roles for tumor cell–stromal crosstalk in establishing chemoresistance are complex and largely unclear. Here we report molecular studies of paired TNBC patient–derived xenografts (PDXs) established before and after the development of chemoresistance. Interestingly, the chemoresistant model acquired a distinct KRAS Q61R mutation that activates K-Ras. The chemoresistant KRAS-mutant model showed gene expression and proteomic changes indicative of altered tumor cell metabolism. Specifically, KRAS-mutant PDXs exhibited increased redox ratios and decreased activation of AMPK, a protein involved in responding to metabolic homeostasis. Additionally, the chemoresistant model exhibited …
引用总数
学术搜索中的文章